COL25A1 and METAP1D DNA methylation are promising liquid biopsy epigenetic biomarkers of colorectal cancer using digital PCR
Bioinformatics analysis of public databases revealed COL25A1 and METAP1D DNA methylation as clinically applicable liquid biopsies DNA methylation biomarkers. The specificity implies an excellent positive predictive value for follow-up, and the high sensitivity and relative noninvasiveness of a blood-based test make these biomarkers compatible with colorectal cancer screening. However, the clinical impact of these biomarkers in colorectal cancer screening and follow-up needs to be established in further prospective studies.
Authors
- Alexis Overs (ORCID: https://orcid.org/0000-0002-0131-9713)
- Michaël Herfs (ORCID: https://orcid.org/0000-0002-4382-8997)
- Paul Peixoto (ORCID: https://orcid.org/0000-0001-6302-7823)
- Chloé Molimard (ORCID: https://orcid.org/0000-0001-9578-1652)
- Julien Viot (ORCID: https://orcid.org/0000-0001-7792-0110)
- Éric Hervouet (ORCID: https://orcid.org/0000-0002-4841-7812)
- Jules Durand
- Jean‐Paul Feugeas
- Angélique Vienot (ORCID: https://orcid.org/0000-0002-0381-7601)
- Franck Monnien (ORCID: https://orcid.org/0000-0002-2799-3730)
- Zohair Selmani
- Christophe Borg (ORCID: https://orcid.org/0000-0002-2167-1458)
- Michaël Boyer‐Guittaut (ORCID: https://orcid.org/0000-0001-9540-5593)
Institutions
- Inserm (FR)
- University of Liège (BE)
- Centre Hospitalier Universitaire de Besançon (FR)
- Université Bourgogne Franche-Comté (FR)
Publication Details
- Journal
- Clinical Epigenetics
- Published
- 2024-10-18
- DOI
- https://doi.org/10.1186/s13148-024-01748-1
- Citations
- 7
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 2.00